Clinical Features of Respiratory Syncytial Virus Infection in Neonates: A Single Center Study

Clinical Features of Respiratory Syncytial Virus Infection in Neonates: A Single Center Study

Purpose The aim of this study was to investigate the clinical characteristics of Respiratory syncytial virus (RSV) infection during the neonatal period to provide information that is useful in clinical practice and suggest extension of the palivizumab administration. Methods Neonates admitted to the...

Full description

Bibliographic Details
Main Authors:	Sung Hui Chang, Gwang Cheon Jang, Shin Won Yoon
Format:	Article
Language:	English
Published:	Korean Society of Neonatology 2018-11-01
Series:	Neonatal Medicine
Subjects:	respiratory syncytial viruses newborn palivizumab post-natal care center
Online Access:	http://www.neo-med.org/upload/pdf/nm-2018-25-4-144.pdf

Similar Items

Patient equity and respiratory syncytial virus Immunoprophylaxis
by: H. Cody Meissner
Published: (2019-01-01)

Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection
by: Hasindu S. Edirisinghe, et al.
Published: (2023-11-01)

Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?
by: Alessandro Rocca, et al.
Published: (2021-04-01)

Respiratory syncytial virus outbreak in neonatal intensive care unit: Impact of infection control measures plus palivizumab use
by: Silva Camila de A, et al.
Published: (2012-05-01)

Respiratory syncytial virus seasonality in Brazil: implications for the immunisation policy for at-risk populations
by: André Ricardo Ribas Freitas, et al.
Published: (2016-01-01)

Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil
by: Roseane Porfírio de Souza, et al.
Published: (2019-08-01)

Resurgence of Respiratory Syncytial Virus in Children: An Out-of-Season Epidemic in Portugal
by: Ana Rita Torres, et al.
Published: (2023-01-01)

Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia
by: Jaime E. Ordóñez, et al.
Published: (2024-04-01)

Pathophysiological mechanisms for the respiratory syncytial virus-reactive airway disease link
by: Piedimonte Giovanni
Published: (2002-06-01)

Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing
by: Kimpen Jan LL
Published: (2002-06-01)

Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children
by: Natividad Viguria, et al.
Published: (2021-06-01)

Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era
by: Bernhard Resch, et al.
Published: (2017-04-01)

Temporal-spatial analysis of hospitalizations for bronchiolitis in Brazil: prediction of epidemic regions and periods for immunization against the Respiratory Syncytial Virus
by: Edilenia Queiroz Pereira, et al.
Published: (2023-03-01)

One‐year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America
by: Leandro Martin Castillo, et al.
Published: (2017-09-01)

Regional impact of prophylaxis with the monoclonal antibody palivizumab on ospitalizations from respiratory syncytial virus in infants
by: Swiss Medical Weekly
Published: (2001-03-01)

Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29–34 6/7 weeks' gestation in the United States
by: Tianzhou Yu, et al.
Published: (2024-03-01)

Detection of the Onset of the Epidemic Period of Respiratory Syncytial Virus Infection in Japan
by: Hidetomi Yamagami, et al.
Published: (2019-03-01)

Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006–2010
by: Jesse Papenburg, et al.
Published: (2012-01-01)

RESPIRATORY SYNCYTIAL VIRUS INFECTION IN INFANTS
by: K. V. YEVDOKIMOV, et al.
Published: (2017-05-01)

The clinical significance of palivi-zumab in the prevention of severe respiratory infections in newborn infants
by: Bykova Е.М., et al.
Published: (2016-06-01)

Palivizumab e virus respiratorio sinciziale: una panoramica
by: Paolo Manzoni
Published: (2011-07-01)

The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence
by: Antonino Capizzi, et al.
Published: (2017-08-01)

Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada
by: Rodica Gilca, et al.
Published: (2020-12-01)

Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation
by: D Wang, et al.
Published: (2008-12-01)

Survival of recombinant monoclonal and naturally-occurring human milk immunoglobulins A and G specific to respiratory syncytial virus F protein across simulated human infant gastrointestinal digestion
by: Jiraporn Lueangsakulthai, et al.
Published: (2020-10-01)

Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain
by: Ralph Schmidt, et al.
Published: (2017-12-01)

Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection
by: Bernhard Resch
Published: (2017-09-01)

Evaluation of respiratory complications in a cohort of preterm infants who did not receive palivizumab monoclonal antibodies
by: Poliana Castro de Resende Bonati, et al.
Published: (2022-10-01)

Perinatal respiratory infections and long term consequences
by: Luciana Indinnimeo, et al.
Published: (2015-10-01)

Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab
by: Mariana Bueno Manini, et al.

Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: systematic review and additional economic modelling of subgroup analyses
by: D Wang, et al.
Published: (2011-01-01)

Clinical characteristics of respiratory syncytial virus infection in neonates and young infants
by: Savić Nataša, et al.
Published: (2011-01-01)

Neonatal Genetic Delivery of Anti-Respiratory Syncytial Virus (RSV) Antibody by Non-Human Primate-Based Adenoviral Vector to Provide Protection against RSV
by: Rika Gomi, et al.
Published: (2018-12-01)

Neonatal Calf Infection with Respiratory Syncytial Virus: Drawing Parallels to the Disease in Human Infants
by: Timothy A. Reinhardt, et al.
Published: (2012-12-01)

Comparison of indirect and direct immunofluorescence for the detection of Respiratory Syncytial Virus
by: Stefano Gambarino, et al.
Published: (2009-12-01)

RSV Disease Threat and Innovative Prevention Methods in Health Protection: A Review
by: Paulina Dąbrowska, et al.
Published: (2024-02-01)

Partial Degradation of Recombinant Antibody Functional Activity During Infant Gastrointestinal Digestion: Implications for Oral Antibody Supplementation
by: Baidya Nath P. Sah, et al.
Published: (2020-08-01)

Functional Features of the Respiratory Syncytial Virus G Protein
by: Larry J. Anderson, et al.
Published: (2021-07-01)

Risk of mortality associated with respiratory syncytial virus and influenza infection in adults
by: Yong Shik Kwon, et al.
Published: (2017-12-01)

Addendum to Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level
by: Ian G. Barr, et al.
Published: (2022-03-01)